245 related articles for article (PubMed ID: 20537128)
1. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.
Detke HC; McDonnell DP; Brunner E; Zhao F; Sorsaburu S; Stefaniak VJ; Corya SA
BMC Psychiatry; 2010 Jun; 10():43. PubMed ID: 20537128
[TBL] [Abstract][Full Text] [Related]
2. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
McDonnell DP; Detke HC; Bergstrom RF; Kothare P; Johnson J; Stickelmeyer M; Sanchez-Felix MV; Sorsaburu S; Mitchell MI
BMC Psychiatry; 2010 Jun; 10():45. PubMed ID: 20537130
[TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.
Atkins S; Detke HC; McDonnell DP; Case MG; Wang S
BMC Psychiatry; 2014 Jan; 14():7. PubMed ID: 24423017
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.
Bushe CJ; Falk D; Anand E; Casillas M; Perrin E; Chhabra-Khanna R; Detke HC
BMC Psychiatry; 2015 Apr; 15():65. PubMed ID: 25886006
[TBL] [Abstract][Full Text] [Related]
5. [Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].
Buts K; Van Hecke J
Tijdschr Psychiatr; 2014; 56(4):273-6. PubMed ID: 24807388
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.
Detke HC; Zhao F; Witte MM
BMC Psychiatry; 2012 May; 12():51. PubMed ID: 22646847
[TBL] [Abstract][Full Text] [Related]
7. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP
BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159
[TBL] [Abstract][Full Text] [Related]
8. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
Novakovic V; Adel T; Peselow E; Lindenmayer JP
Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.
McDonnell DP; Landry J; Detke HC
Int Clin Psychopharmacol; 2014 Nov; 29(6):322-31. PubMed ID: 24850228
[TBL] [Abstract][Full Text] [Related]
10. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
[TBL] [Abstract][Full Text] [Related]
11. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.
Detke HC; Weiden PJ; Llorca PM; Choukour M; Watson SB; Brunner E; Ascher-Svanum H
J Clin Psychopharmacol; 2014 Aug; 34(4):426-34. PubMed ID: 24781441
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
[TBL] [Abstract][Full Text] [Related]
13. Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?
Łukasik-Głębocka M; Sommerfeld K; Teżyk A; Panieński P; Żaba C; Zielińska-Psuja B
Basic Clin Pharmacol Toxicol; 2015 Sep; 117(3):213-4. PubMed ID: 25703610
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine: a review of rapid and long-acting parenteral formulations.
Owen RT
Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591
[TBL] [Abstract][Full Text] [Related]
15. Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.
Ascher-Svanum H; Novick D; Haro JM; Bertsch J; McDonnell D; Detke H
BMC Psychiatry; 2013 Sep; 13():224. PubMed ID: 24041270
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine pamoate for the treatment of schizophrenia.
Naber D
Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
[TBL] [Abstract][Full Text] [Related]
17. Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy.
Case MG; Karagianis JL; Schuh KJ; Hoffmann VP
Curr Med Res Opin; 2013 Nov; 29(11):1533-7. PubMed ID: 23998459
[TBL] [Abstract][Full Text] [Related]
18. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.
Ascher-Svanum H; Zhao F; Detke HC; Nyhuis AW; Lawson AH; Stauffer VL; Montgomery W; Witte MM; McDonnell DP
BMC Psychiatry; 2011 Sep; 11():152. PubMed ID: 21943257
[TBL] [Abstract][Full Text] [Related]
19. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.
Luedecke D; Schöttle D; Karow A; Lambert M; Naber D
CNS Drugs; 2015 Jan; 29(1):41-6. PubMed ID: 25424243
[TBL] [Abstract][Full Text] [Related]
20. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.
Hill AL; Sun B; Karagianis JL; Watson SB; McDonnell DP
BMC Psychiatry; 2011 Feb; 11():28. PubMed ID: 21324135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
